The difference between Carfilzomib and Velcade

Velcade is the brand name of Bortezomib (Bortezomib) marketed in China. Carfilzomib (Carfilzomib) and bortezomib are both drugs used to treat multiple myeloma (Multiple Myeloma), but they have some significant differences in their mechanisms of action, usage, adverse reactions, and efficacy. Carfilzomib belongs to the proteasome inhibitor class of drugs. It inhibits the normal degradation of proteins by interfering with the function of the proteasome. This leads to the accumulation of abnormal proteins inside the cancer cells, ultimately leading to the death of the cancer cells. Bortezomib is also a proteasome inhibitor, but its mechanism of action is different from that of carfilzomib. It interferes with protein degradation in cancer cells by interacting with specific enzymes within the proteasome, leading to cancer cell death.